Overview

Radcliffe Medical Education is hosting a symposium entitled 'Revolutionising Thrombosis Treatment in ACS, SSP and AF: Bridging the Gaps With Next Generation Anticoagulation Strategies' at the European Society of Cardiology Congress (ESC) in Madrid (ES) on Friday 29 August 2025 at 10:00–10:45 CEST. 

Join Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Palo Alto, US) and Prof Jeffrey Weitz (Hamilton, CA) as they examine the prevalence and challenges of stroke prevention in AF and ACS, review the guidelines for current treatments strategies, as well as exploring factor XI and innovations in antithrombotics, clinical trials and how these may shape clinical practice. 

Learning Objectives 
After attending this symposium, physicians will be able to:

• Discuss the unmet needs in thrombosis management, stroke burden in ACS and AF and secondary stroke prevalence and consequence
• Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
• Review guidelines and critique current prescribing practices and the implications of inadequate treatment
• Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional antithrombotic therapies
• Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
• Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors
   

Programme 
Part 1 - Welcome
Part 2 - Stroke Prevention in AF and ACS: Prevalence and Challenges
Part 3 - Current Treatments in AF and ACS, Safety and Guidelines 
Part 4 - Targeting Factor XI: Innovations in Antithrombotic and Clinical Trials 
Part 5 - Shaping Clinical Practice and Patient Impact 
Part 6 - Audience Q&A and Closing Remarks
 

This satellite symposium is supported by an unrestricted educational grant from Bristol Myers Squibb and its Alliance partner Janssen Pharmaceuticals, Inc.

Can’t attend ESC 2025? Click below to get notified when the session is available to watch on demand.